Private Advisor Group LLC Has $3.07 Million Holdings in GlaxoSmithKline PLC (NYSE:GSK)

Private Advisor Group LLC grew its holdings in shares of GlaxoSmithKline PLC (NYSE:GSK) by 1.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 72,764 shares of the pharmaceutical company’s stock after acquiring an additional 1,055 shares during the quarter. Private Advisor Group LLC’s holdings in GlaxoSmithKline PLC were worth $3,072,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Bronfman E.L. Rothschild L.P. raised its stake in GlaxoSmithKline PLC by 45.4% during the first quarter. Bronfman E.L. Rothschild L.P. now owns 2,410 shares of the pharmaceutical company’s stock worth $102,000 after acquiring an additional 753 shares in the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC grew its holdings in shares of GlaxoSmithKline PLC by 1,747.4% during the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 2,494 shares of the pharmaceutical company’s stock worth $105,000 after purchasing an additional 2,359 shares during the last quarter. Proficio Capital Partners LLC grew its holdings in shares of GlaxoSmithKline PLC by 233.0% during the first quarter. Proficio Capital Partners LLC now owns 2,844 shares of the pharmaceutical company’s stock worth $122,000 after purchasing an additional 1,990 shares during the last quarter. Heritage Trust Co bought a new stake in shares of GlaxoSmithKline PLC during the first quarter worth about $123,000. Finally, Westwood Holdings Group Inc. grew its holdings in shares of GlaxoSmithKline PLC by 15.7% during the first quarter. Westwood Holdings Group Inc. now owns 2,950 shares of the pharmaceutical company’s stock worth $124,000 after purchasing an additional 400 shares during the last quarter. 9.29% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by BBNS and is the property of of BBNS. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international copyright & trademark law. The original version of this piece of content can be read at https://baseballnewssource.com/markets/private-advisor-group-llc-boosts-stake-in-glaxosmithkline-plc-gsk/1604555.html.

Several research firms have recently weighed in on GSK. Citigroup Inc. cut GlaxoSmithKline PLC from a “buy” rating to a “neutral” rating in a report on Wednesday, July 5th. J P Morgan Chase & Co restated a “neutral” rating on shares of GlaxoSmithKline PLC in a report on Thursday. ValuEngine cut GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. BidaskClub cut GlaxoSmithKline PLC from a “sell” rating to a “strong sell” rating in a report on Monday, July 24th. Finally, TheStreet cut GlaxoSmithKline PLC from a “b” rating to a “c+” rating in a report on Wednesday, July 26th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $46.00.

GlaxoSmithKline PLC (NYSE:GSK) traded down 0.5274% during trading on Friday, hitting $40.1372. The company’s stock had a trading volume of 1,384,052 shares. The firm has a market cap of $98.10 billion, a P/E ratio of 39.6613 and a beta of 1.03. GlaxoSmithKline PLC has a 12 month low of $37.20 and a 12 month high of $44.54. The firm has a 50 day moving average of $39.82 and a 200 day moving average of $41.78.

GlaxoSmithKline PLC (NYSE:GSK) last announced its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 EPS for the quarter, topping the Zacks’ consensus estimate of $0.68 by $0.02. The business had revenue of $9.36 billion for the quarter, compared to analysts’ expectations of $9.52 billion. GlaxoSmithKline PLC had a return on equity of 114.93% and a net margin of 6.48%. Equities research analysts predict that GlaxoSmithKline PLC will post $2.87 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 12th. Stockholders of record on Friday, August 11th will be given a $0.491 dividend. This is a positive change from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. This represents a $1.96 dividend on an annualized basis and a dividend yield of 4.87%. The ex-dividend date is Wednesday, August 9th. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is currently 197.00%.

GlaxoSmithKline PLC Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with our FREE daily email newsletter.

 


Latest News

New Home Run Record Reached in Major League Baseball
New Home Run Record Reached in Major League Baseball
Will 2017 MLB Season End with No 20-Game Winner?
Will 2017 MLB Season End with No 20-Game Winner?
Cleveland Indians Winning Streak Snapped at 22
Cleveland Indians Winning Streak Snapped at 22
Tigers Player Might Play All Nine Positions During Same Game
Tigers Player Might Play All Nine Positions During Same Game
Fans Kicked Out of Fenway Park After Racist Banner Hung on Green Monster
Fans Kicked Out of Fenway Park After Racist Banner Hung on Green Monster
Dodgers End Losing Streak at 11 Behind Ace Clayton Kershaw
Dodgers End Losing Streak at 11 Behind Ace Clayton Kershaw


Leave a Reply

 
© 2006-2017 BBNS.